Allarity Therapeutics, Inc. (ALLR) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Allarity Therapeutics, Inc.

ALLR

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

19M

Biotechnology

Next Earning date - 13 May 2025

19M

Biotechnology

Next Earning date - 13 May 2025

1.13USD

0.06 ( 5.61%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-16%

Earning Acce

Dist 52w H.

99%

Overview Chart

Quote Panel

Updated April 27, 2025

1W 9.71 % 1M 8.65 % 3M -21.53 % 1Y -97.27 %

Key Metrics

Market Cap
19.23M
Shares Outstanding
17.01M
Share in Float
13.00M
Dividende
0

Earning Date
13 May 2025
Price Target
1.13
Average Volume
2.01M
Beta
-0.073

Range
0.614-103.8
Industry
Biotechnology
Website
https://www.allarity.com
Sector
Healthcare

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

0.06x

P/B Ratio

0.1

Debt/Equity

0.0%

Net Margin

$-15.7

EPS

How ALLR compares to sector?

P/E Ratio

Fundamentals

Relative Strength

ALLR

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

ALLR

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$49M

NaN%

2025-Revenue

$46.80

NaN%

2025-EPS

$29M

495%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Hold

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-604800.60
vs 181.2K

Q4.22

N/A

-0.23
vs -2143780.88

Q1.23

N/A

-106426.40
vs -312148.14

Q2.23

N/A

-15783.78
vs -0.52

Q3.23

N/A

-1345.35
vs -604800.60

Q4.23

N/A

-0.43
vs -0.23

Q1.24

N/A

-664.86
vs -106426.40

Q2.24

N/A

-3.30
vs -15783.78

Q3.24

N/A

-7.71
vs -1345.35

Q4.24

N/A

NA
vs -0.43

Sales Growth

YoY

Current

Estimates

Q3.22

NA vs NA

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

112K vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 112K

Return on Equity

QoQ

Q1.23

+927%

9.27
vs -1.50

Q2.23

+329%

3.29
vs 9.27

Q3.23

+164%

1.64
vs 3.29

Q4.23

+63%

0.63
vs 1.64

Q1.24

+59%

0.59
vs 0.63

Q2.24

-8%

-0.08
vs 0.59

Q3.24

-94%

-0.94
vs -0.08

Q4.24

-63%

-0.63
vs -0.94

Institutionnal Ownership

QoQ

Q4.21

2
vs NA

Q1.22

9
vs 2

350%

Q2.22

8
vs 9

-11%

Q3.22

8
vs 8

Q4.22

10
vs 8

25%

Earnings Growth

Latest News

prnewswire.com

3 hours ago

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

prnewswire.com

4 hours ago

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

accessnewswire.com

7 hours ago

Shareholder Rights Advocates at Levi & Korsinsky Investigate Allarity Therapeutics, Inc. (ALLR) Regarding Possible Securities Fraud Violations

prnewswire.com

9 hours ago

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

prnewswire.com

9 hours ago

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

accessnewswire.com

16 hours ago

Levi & Korsinsky Announces an Investigation on Behalf of Allarity Therapeutics, Inc. (ALLR) Shareholders Who May Have Been Affected by Fraud

Company Description

1.13USD

N/A

0.00x

0.06x

0.1

0.0%

$-15.7

$49M

$46.80

$29M

Earnings Growth

Latest News

Company Description

1.13USD

N/A

0.00x

0.06x

0.1

0.0%

$-15.7